A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Cervical cancer
- Focus Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 21 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
- 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.
- 03 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.